A panel of health and infectious disease experts has advised the continued use of the AstraZeneca COVID-19 vaccine.

In a press release Monday, South Korea's vaccination expert committee said that domestic and foreign data confirm there is no correlation between the vaccine and blood clots.

But the committee added that very rare cases of disseminated intravascular coagulation(DIC) and cerebral venous sinus thrombosis(CVST) reported in one out of one million people require further study.

The panel's statement echoes the views of the World Health Organization, the European Medicines Agency and the U.K. Medicines and Healthcare Products Regulatory Agency.

South Korea is set to begin vaccinating around 376-thousand inpatients and employees aged over 65 at nursing homes and long-term care facilities starting Tuesday.

Shots for the older age group originally scheduled in February were withheld following controversy around the safety of AstraZeneca's vaccine.